ThermoGenesis Holdings, Inc. · OTC:THMO
ThermoGenesis — Cesca Therapeutics — Investor Presentation (November 2017)
24 slides from ThermoGenesis's investor presentation, Nov 15, 2017
Slide 1: Clinical Excellence and Stem Cell Applications
Exhibit 99.1 SK A Boyalife _/\ Clinical Excellefigiadn Stem Cell Applications Developing Capacities for the Future Medicine Fully Automated Cellular Processing & Applications X. Chris Xu, PhD, MBA Chairman & CEO Cesca Therapeutics Inc. November 14, 2017
Slide 2: Forward looking statement
Forward looking statement This presentation includes statements of future expectations and other forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current views and assumpt
Slide 3: Who we are?
Who we are? Cesca, founded in 1986, is a leading medical technology company developing state-of-the art automated cellular processing devices for the stem cell industry, and is now leveraging its expertise for the immune cell-based therapeutics, such as CAR-T therapies. Two key areas of focus are: =
Slide 4: Cesca highlights
Cesca highlights CAR-T represents a significant advancement in the treatment of many cancers, but as “personalized” therapies, cost and time to delivery are significant industry obstacles Cesca has developed a unique, cutting-edge platform for automated CAR-T manufacturing that improves speed, consi
Slide 5: Financial snapshot
Financial snapshot Share Price* $3.58 52-Week Range $2.41 - $6.44 Shares Outstanding 9.9M Market Capitalization $35.4M Revenue (TTM)** $14M Cash** $2.5M Largest Shareholder Boyalife Group (70%) * November 13, 2017 ** September 30, 2017 5| NASDAQ: KOOL
Slide 6: Cell-based therapeutics — the next pillar of medicine
Cell-based therapeutics — the next pillar of medicine Cell-based therapeutics — next pillar of medicine M.A. Fischbach, J.A. Bluestone and W.A. Lim —— Science Translational Medicine, Vol. 5, Issue 179, pp.179 Two decades ago, the pharmaceutical industry—long dominated by small- molecule drugs—was re
Slide 7: First CAR-T therapy approved, but expensive
irst CAR-T therapy approved, but expensive ( »,000/per patient) Emily's Story: A Young Girl Beats Cancer with SENS 2008 NG SUI TEO as 129? Immunotherapy Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes Richard A. Morgan, Mark E. Dudley, John R. Wunderlich, Marybeth
Slide 8: FDA OKs second gene therapy for cancer
FDA OKS SECOND GENE THERAPY FOR CANCER October 19, 2017 8| NASDAQ: KOOL
Slide 9: Why is CAR-T so expensive? — the current manufacturing processes
Why is CAR-T so expensive? — the current manufacturing processes — Manual or semi-automated, lengthy, low yield, lack of efficiency > high cost Apheresis product wash/fractionation Ps: 2991, Cell Saver 5, LOVO,Elutra, Sepax, Prodigy Apheresis collection a T-cell cryopreservation *\ comotatsa freezer
Slide 10: Introduction to Cesca's CAR-TXpress platform
Introduction to Cesca’s CAR-TXpress™ platform Improving manufacturing capabilities for medicines of the future Fully automated, functionally closed system, for CAR-T cell CMC manufacturing, providing a high-efficient, low-cost enabling tool for developers of CAR-T therapies. 10 | NASDAQ: KOOL
Slide 11: Why we can do it - leveraging expertise & industry know-how
hy we can do it - leveraging expertise & industry know-how Cesca Is the leader in automation technology for cell therapeutics Point-of-Care/Lab-based Partial list of global clients Over 100 clients in > 40 countries cGMP — New York ceed Systems & Blood Center Scalable ° cordlife TEXAS CRYOLIFE sTéte
Slide 12: Cesca & SynGen — combined core product portfolio
Cesca & SynGen — combined core product portfolio — In July, 2017, Cesca acquired SynGer! to develop automations for CAR-T therapies AXP™ } MxP™ -For cord blooc ¢/) { -PoC device for banking i: bone marrow BioArchive™ -Automated cryo- preservation X-1000™ -For cord bloo’ ,® banking a= SynGen Product
Slide 13: Development of CAR-TXpress platform
Development of CAR-TXpress™ platform —— Automated, fully closed system for large scale manufacturing of CAR-T cells with high efficiency :* joleBlood BMA. Leukapheresis Unit IL-2, CD3, Volumes May Exceed 5 L DNA Gene Insertion Additional IL-2 Infused Selection of CI Volume aa ea a [ Se Dama Redcoane
Slide 14: Core technology — X-LAB for high efficiency MNC isolation
Core technology — X-LAB™ for high efficiency MNC isolation —WNon-ficoll based isolation of MNCs from various sources (blood, leukopheresis) ‘axis ofrotation of awing bucket centrfugeis parllelto the floor ASmLMedium] predepositedin T harvest chamber 2000%9, 20 min 50x93 min TNCs & PLTs 20x91 min 50x
Slide 15: Core technology — X-BACS, buoyancy activated cell sorting
Core technology — X-BACS™, buoyance activated cell sorting What It Is: + BACS uses microscopic bubbles (each smaller than a single cell) as cell isolation reagents. * The microbubbles are ruggedized with lipid shells, to which antibodies are attached to bind them only to the target cell type in a mi
Slide 16: Core technology — X-WASH for washing & reformulation
Core technology — X-WASH™ for washing & reformulation High efficiency washing and re-formulation technology Cell suspension added to buffer in central chamber; buffer added to harvest chamber Cartridge snapped on to Control (3] Retrieve Washed Cells Module, placed in centrifuge ‘Washed cells re-susp
Slide 17: Core technology — BioArchive
Core technology — BioArchive® —First and ONLY automated single cassette liquid N, system for clinical sample storage Retrieval cartridge with Sample in overwrap bag canister sleeve and placed in caniste canister in sleeve. Once the sample reaches BioArchive® the first in class single storage device
Slide 18: CAR-TXpress platform — a major leap in CMC manufacturing
Car-txpress platform — a major leap in CMC manufacturing — fully automated closed system for large scale CAR-T biomanufacturing 8 |MNC Isolation MING isolation 90 aa = MNC& CD3+ Selection = MNC & CD34+ Selection wo} oe 0 g7 Eo E 60 8 E 0 gx 8 go; : 40 * 20 30 8 2 4 20 - 6 : ° CARTXpress” Corps nolo
Slide 19: Processing report for CGMP compliance
Processing report for CGMP compliance —— CAR-TXpress™ is designed to be in compliance with CMC manufacturing requirements 19 | NASDAQ: KOOL SynGenX™ Processing Report Unit 1D: cua54T-Reg fi exPoRT | = save RS POF [fay PRINT | 100 © Process Conon 6 od Process ae Time (Seconds) User 1D: inerea Depleti
Slide 20: Growth strategy
Growth strategy Our goal is to become the leading provider of automation for cell-based therapeutics by capturing the rapidly growing immuno-oncology market. A Cc = Stem Cell & CAR-T & Regenerative Medicine Immuno-Oncology Device Clinical CAR-TXpress™ “~~ Ss oS BioBanking Point-of-Care CLI (Ph Ill)
Slide 21: How have we executed?
How have we executed? Achievements and Milestones over the past 12 months Implementation of new strategic vision and corporate goals Strengthened board of directors New executive team with proven track record: CEO & COO Closed strategic acquisition of SynGen Inc. Secured international distribution a
Slide 22: Investment highlights
Bene ee Ne 50 ne 9 oe oe oe eee ieee Investment highlights > Well-positioned to be a leading player in automated CAR-T and CAR-NK cell CMC manufacturing > Able to leverage the strong growth of the immuno-oncology market > Strong IP position covering our cutting-edge BACS cell separation technology >
Slide 23: Experienced leadership team
Experienced leadership team Chris Xu, PhD/MBA, Chairman, President and Chief Executive Officer Boyalife Group (founder), Pfizer, Founder Group Joined Cesca in March 2016 as Director, becoming CEO in Nov 2016 Vivian Liu, Chief Operating Officer and Director OxOnc Services Company, Apricus Biosciences
Slide 24: Investor Contact
Investor Contact: Paula Schwartz RX Communications [email protected] 917-322-2216 Thank You!
Cesca Therapeutics — Investor Presentation (November 2017) on 6ix